These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 27061561)

  • 1. Decitabine+ CAG +DLI in relapsed acute myeloid leukemia after allogeneic stem cell transplantation.
    Wang B; Jin X; Wang Q; Jing Y
    J BUON; 2016; 21(1):280-1. PubMed ID: 27061561
    [No Abstract]   [Full Text] [Related]  

  • 2. D-CAG (decitabine followed by cytarabine, aclarubicin, and G-CSF) for relapsed acute myeloid leukemia after hematopoietic cell transplantation.
    Zheng R; Xie B; Wang C; Yu B; Xu J; Tan H
    Ann Hematol; 2016 Jan; 95(1):157-159. PubMed ID: 26382274
    [No Abstract]   [Full Text] [Related]  

  • 3. Successful treatment of post-transplant relapsed acute myeloid leukemia with FLT3 internal tandem duplication using the combination of induction chemotherapy, donor lymphocyte infusion, sorafenib and azacitidine. Report of three cases.
    Campregher PV; Mattos VRP; Salvino MA; Santos FPS; Hamerschlak N
    Einstein (Sao Paulo); 2017; 15(3):355-358. PubMed ID: 28746590
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Venetoclax plus azacitidine and donor lymphocyte infusion in treating acute myeloid leukemia patients who relapse after allogeneic hematopoietic stem cell transplantation.
    Zhao P; Ni M; Ma D; Fang Q; Zhang Y; Li Y; Huang Y; Chen Y; Chai X; Zhan Y; Li Y; Kang Q; Zhao M; Liu M; Zhang F; Huang S; Wen S; Deng B; Wang J
    Ann Hematol; 2022 Jan; 101(1):119-130. PubMed ID: 34568973
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Decitabine in patients with relapsed acute myeloid leukemia (AML) after allogeneic stem cell transplantation (allo-SCT).
    Ganguly S; Amin M; Divine C; Aljitawi OS; Abhyankar S; McGuirk JP
    Ann Hematol; 2013 Apr; 92(4):549-50. PubMed ID: 23111661
    [No Abstract]   [Full Text] [Related]  

  • 6. Chemotherapy followed by modified donor lymphocyte infusion as a treatment for relapsed acute leukemia after haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion: superior outcomes compared with chemotherapy alone and an analysis of prognostic factors.
    Yan CH; Wang JZ; Liu DH; Xu LP; Chen H; Liu KY; Huang XJ
    Eur J Haematol; 2013 Oct; 91(4):304-14. PubMed ID: 23837640
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Donor lymphocyte infusion for the treatment of relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation: a retrospective analysis by the Adult Acute Myeloid Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation.
    Takami A; Yano S; Yokoyama H; Kuwatsuka Y; Yamaguchi T; Kanda Y; Morishima Y; Fukuda T; Miyazaki Y; Nakamae H; Tanaka J; Atsuta Y; Kanamori H
    Biol Blood Marrow Transplant; 2014 Nov; 20(11):1785-90. PubMed ID: 25034960
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Studies of decitabine with allogeneic progenitor cell transplantation.
    Giralt S; Davis M; O'Brien S; van Besien K; Champlin R; de Vos D; Kantarjian H
    Leukemia; 1997 Mar; 11 Suppl 1():S32-4. PubMed ID: 9130690
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of AML and MDS relapsing after reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation.
    Oran B; Giralt S; Couriel D; Hosing C; Shpall EJ; de Meis E; Khouri IF; Qazilbash M; Anderlini P; Kebriaei P; Popat U; Carrasco-Yalan A; Champlin RE; de Lima M
    Leukemia; 2007 Dec; 21(12):2540-4. PubMed ID: 17611563
    [No Abstract]   [Full Text] [Related]  

  • 10. [Clinical efficacy of decitabine plus improved CAG chemotherapy and haplo-identical donor peripheral lymphocyte infusion regimen on elderly patients with high risk myelodysplastic syndrome and acute myeloid leukemia].
    Dou LP; Jing Y; Wang QS; Mei JH; Yu L
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Jun; 21(3):662-6. PubMed ID: 23815918
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted anti-leukemic therapy as disease-stabilizing treatment for acute myeloid leukemia relapse after allogeneic stem cell transplantation: Will it be possible to combine these strategies with retransplantation or donor lymphocyte infusions?
    Reikvam H; Kittang AO; Melve G; Mosevoll KA; Bentsen PT; Ersvær E; Gjertsen BT; Bruserud Ø
    Curr Cancer Drug Targets; 2013 Jan; 13(1):30-47. PubMed ID: 22873213
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factors affecting survival in acute leukemia with donor lymphocyte infusion in the first relapse after allogeneic stem cell transplantation.
    Kurnaz F; Sahin C; Kaynar L; Pala C; Sivgin S; Altuntas F; Eser B; Cetin M; Unal A
    J BUON; 2016; 21(1):227-34. PubMed ID: 27061552
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of acute myeloid leukemia or myelodysplastic syndrome relapse after allogeneic stem cell transplantation with azacitidine and donor lymphocyte infusions--a retrospective multicenter analysis from the German Cooperative Transplant Study Group.
    Schroeder T; Rachlis E; Bug G; Stelljes M; Klein S; Steckel NK; Wolf D; Ringhoffer M; Czibere A; Nachtkamp K; Dienst A; Kondakci M; Stadler M; Platzbecker U; Uharek L; Luft T; Fenk R; Germing U; Bornhäuser M; Kröger N; Beelen DW; Haas R; Kobbe G
    Biol Blood Marrow Transplant; 2015 Apr; 21(4):653-60. PubMed ID: 25540937
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Post-transplant maintenance therapy with azacitidine and gemtuzumab ozogamicin for high-risk acute myeloid leukaemia.
    Oshikawa G; Kakihana K; Saito M; Aoki J; Najima Y; Kobayashi T; Doki N; Sakamaki H; Ohashi K
    Br J Haematol; 2015 Jun; 169(5):756-9. PubMed ID: 25522128
    [No Abstract]   [Full Text] [Related]  

  • 15. Treatment of relapsed acute myeloid leukemia with MLL/AF6 fusion after allogeneic hematopoietic stem cell transplantation with gemtuzumab ozogamicin with a long interval followed by donor lymphocyte infusion.
    Tamai H; Shioi Y; Yamaguchi H; Okabe M; Wakita S; Mizuki T; Nakayama K; Inokuchi K; Tajika K; Dan K
    Leukemia; 2008 Jun; 22(6):1273-4. PubMed ID: 17989711
    [No Abstract]   [Full Text] [Related]  

  • 16. PD1 inhibitor in combination with 5-azacytidine and low-dose DLI for the successful treatment of AML patients who relapsed after transplantation.
    Qian CS; Ma X; Wang J; Wang TJ; Bai L; Zhou HX; Xu MZ; Sun AN; Wu DP; Liu SB; Xue SL
    Bone Marrow Transplant; 2021 May; 56(5):1003-1005. PubMed ID: 33214690
    [No Abstract]   [Full Text] [Related]  

  • 17. Long-term follow-up of a phase I study of high-dose decitabine, busulfan, and cyclophosphamide plus allogeneic transplantation for the treatment of patients with leukemias.
    de Lima M; Ravandi F; Shahjahan M; Andersson B; Couriel D; Donato M; Khouri I; Gajewski J; van Besien K; Champlin R; Giralt S; Kantarjian H
    Cancer; 2003 Mar; 97(5):1242-7. PubMed ID: 12599231
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decitabine as a conditioning regimen in haploidentical stem cell transplantation for refractory acute myeloid leukaemia.
    Zhang C; Chen XH; Liu J; Gao L; Liu Y; Gao L; Kong PY; Zhang X
    J Clin Pharm Ther; 2015 Jun; 40(3):336-8. PubMed ID: 25825260
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of a 3-day, low-dose treatment with 5-azacytidine followed by donor lymphocyte infusions in older patients with acute myeloid leukemia or chronic myelomonocytic leukemia relapsed after allografting.
    Lübbert M; Bertz H; Wäsch R; Marks R; Rüter B; Claus R; Finke J
    Bone Marrow Transplant; 2010 Apr; 45(4):627-32. PubMed ID: 19718057
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effect of decitabine on immune regulation in patients with acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation].
    Wang J; Zhou J; Zheng HF; Fu ZZ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Oct; 22(5):1448-52. PubMed ID: 25338605
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.